A European review committee has recommended that British company GW Pharmaceuticals’ Epidyolex (known as Epidiolex in the US) be licensed as a medicine in the European Union. It could become the first official CBD-based medicine available in Europe after the panel recommended the licensing of therapeutic drugs in the union.
Get access to premium content that is normally only available for subscribers. For the duration of a week, you can read our news analysis, identify market trends and understand upcoming changes in the industry, which will enable you to get ahead of your competitors.
Benefits of subscription plans:
Stay informed of any legal and market change in the sector that impacts your organization
Maximise resources by getting market and legal data analysis daily in one place
Make smart decisions by understanding how the regulatory and market landscape evolves
Anticipate risks in your decisions by monitoring regulatory changes that impact your organization
CannIntelligence.com provides independent, in-depth regulatory and market data and intelligence for the global cannabis and cannabinoid sector.
Start your FREE trial
Sign up to access our business and regulatory briefings and get the most updated news, insights and our expert analysis to keep you on top of worldwide industry trends.